Clinical Trials Browser

Phase 1/2 × Carcinoma, Squamous Cell × zalutumumab × Clear all

NCT00707655 2023-08-03

Zalutumumab in Combination With Radiotherapy in Head and Neck Cancer Patients Ineligible for Platinum Based Chemotherapy

Phase 1/2 Terminated

8 enrolled 10 charts

Carcinoma, Squamous Cell, Head and Neck Neoplasms